{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:38:07Z","timestamp":1790811487495,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jconrel.2016.11.025","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T15:12:27Z","timestamp":1479913947000},"page":"95-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":202,"special_numbering":"C","title":["Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges"],"prefix":"10.1016","volume":"245","author":[{"given":"Ming Ming","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha S.","family":"El-Salamouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam M.","family":"El-Refaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"Hazzah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragwa M.","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Blanco-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-1882","authenticated-orcid":false,"given":"Nashiru","family":"Billa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira S.","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jab.2015.07.004","article-title":"Alzheimer's disease: potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline \u2014 a review study","volume":"13","author":"Klimova","year":"2015","journal-title":"J. Appl. Biomed."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","article-title":"2015 \u2014 Alzheimer's disease facts and figures","volume":"11","author":"Alzheimer's","year":"2015","journal-title":"Alzheimer's Dementia"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's Dementia"},{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.jconrel.2016.11.025_bb0025","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.jconrel.2016.11.025_bb0030","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.arcmed.2012.10.017","article-title":"Genetics of Alzheimer's disease","volume":"43","author":"Vilatela","year":"2012","journal-title":"Arch. Med. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jalz.2011.11.005","article-title":"Benefits of combined cholinesterase inhibitor and memantine treatment in moderate\u2013severe Alzheimer's disease","volume":"9","author":"Gauthier","year":"2013","journal-title":"Alzheimer's Dementia"},{"issue":"5","key":"10.1016\/j.jconrel.2016.11.025_bb0040","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jocn.2003.12.007","article-title":"Alzheimer's disease pathogenesis and therapeutic interventions","volume":"11","author":"Parihar","year":"2004","journal-title":"J. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0045","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer's disease","volume":"34","author":"O'Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0055","first-page":"728","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloidogenic derivative","volume":"255","author":"Glenner","year":"1984","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0060","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","article-title":"The history of the cholinergic hypothesis","volume":"221","author":"Contestabile","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"BBA-Mol. Basis Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer's disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res. Rev."},{"issue":"8","key":"10.1016\/j.jconrel.2016.11.025_bb0085","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbadis.2013.09.010","article-title":"The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives","volume":"1842","author":"Swerdlow","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2012.05.014","article-title":"Targeting drugs to mitochondria","volume":"82","author":"Heller","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0095","series-title":"Side Effects of Drugs Annual","first-page":"1","article-title":"Central nervous system stimulants and drugs that suppress appetite","author":"Aagaard","year":"2014"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0105","article-title":"Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management","volume":"1\u201312","author":"Hanafy","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jddst.2015.07.007","article-title":"The \u201cfate\u201d of polymeric and lipid nanoparticles for brain delivery and targeting: strategies and mechanism of blood\u2013brain barrier crossing and trafficking into the central nervous system","volume":"32","author":"Tosi","year":"2016","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/9781118774205.ch4","article-title":"Nanoparticles for diagnosis and\/or treatment of Alzheimer's disease","volume":"87\u2013179","author":"Antimisiaris","year":"2014","journal-title":"Adv. Healthc. Mater."},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2011.10.007","article-title":"Nanotechnological advances for the delivery of CNS therapeutics","volume":"64","author":"Wong","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"41","key":"10.1016\/j.jconrel.2016.11.025_bb0125","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.2174\/138161281941131219123329","article-title":"Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and Schizophrenia","volume":"19","author":"Silva","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2012.12.013","article-title":"Biocompatibility of engineered nanoparticles for drug delivery","volume":"166","author":"Naahidi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0135","series-title":"Encyclopedia of Nanoscience and Nanotechnology","first-page":"133","article-title":"Advances in nanoparticulate carriers for oral delivery of peptides and proteins: polymeric vs. lipid nanoparticles","author":"Silva","year":"2011"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/mabi.200700165","article-title":"A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization","volume":"8","author":"Craparo","year":"2008","journal-title":"Macromol. Biosci."},{"issue":"28","key":"10.1016\/j.jconrel.2016.11.025_bb0150","doi-asserted-by":"crossref","first-page":"12076","DOI":"10.1039\/C5NR03474D","article-title":"Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases","volume":"7","author":"Fornaguera","year":"2015","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0155","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jcis.2010.09.073","article-title":"Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation","volume":"353","author":"Calder\u00f3","year":"2011","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijbiomac.2014.03.022","article-title":"Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation","volume":"67","author":"Md","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/03639045.2012.758130","article-title":"Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting","volume":"40","author":"Bhavna","year":"2014","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0170","article-title":"Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro","author":"Baysal","year":"2016","journal-title":"J. Neural Transm."},{"issue":"12","key":"10.1016\/j.jconrel.2016.11.025_bb0175","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3109\/03639045.2015.1062897","article-title":"Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain","volume":"41","author":"Hanafy","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","article-title":"Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting","volume":"47","author":"Fazil","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","article-title":"Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies","volume":"76","author":"Joshi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0190","first-page":"18","article-title":"New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation","volume":"2","author":"Khemariya","year":"2016","journal-title":"International Journal of Current Research in Medical Sciences"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0195","article-title":"Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations","volume":"1\u201310","author":"Misra","year":"2015","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2015.03.001","article-title":"Solid lipid nanoparticles loaded with lipoyl\u2013memantine codrug: preparation and characterization","volume":"485","author":"Laserra","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","article-title":"Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters","volume":"78","author":"Shah","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/IJN.S39232","article-title":"Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease","volume":"8","author":"Ismail","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0215","first-page":"205","article-title":"Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil","volume":"10","author":"Al Asmari","year":"2016","journal-title":"Drug Des. Devel. Ther"},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0225","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","article-title":"Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes","volume":"34","author":"Li","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12668-012-0040-y","article-title":"Amyloid-binding aptamer conjugated curcumin\u2013PLGA nanoparticle for potential use in Alzheimer's disease","volume":"2","author":"Mathew","year":"2012","journal-title":"BioNanoScience"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0235","series-title":"Encyclopedia of Nanoscience and Nanotechnology","first-page":"455","article-title":"Lipid nanoparticles in biomedicine","author":"Estella-Hermoso de Mendoza","year":"2011"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.chemphyslip.2014.03.006","article-title":"Drug targeting using solid lipid nanoparticles","volume":"181","author":"Rostami","year":"2014","journal-title":"Chem. Phys. Lipids"},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0245","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijpharm.2015.10.043","article-title":"Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers","volume":"496","author":"El-Salamouni","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/157341309787314656","article-title":"Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer's disease: preparation, characterization and cytotoxicity studies","volume":"5","author":"Bondi","year":"2009","journal-title":"Curr. Nanosci."},{"issue":"25","key":"10.1016\/j.jconrel.2016.11.025_bb0255","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","article-title":"Lipid-based nanoparticles with high binding affinity for amyloid-\u03b21\u201342 peptide","volume":"31","author":"Gobbi","year":"2010","journal-title":"Biomaterials"},{"issue":"42","key":"10.1016\/j.jconrel.2016.11.025_bb0260","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.2174\/1381612821666151027152534","article-title":"Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy","volume":"21","author":"Gonzalez-Fernandez","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2007.06.015","article-title":"Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization","volume":"68","author":"Estella-Hermoso de Mendoza","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0270","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2014.02.004","article-title":"Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications","volume":"180","author":"Elnaggar","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0275","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1007\/s11095-015-1672-8","article-title":"Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in vitro optimization, ex vivo and in vivo permeation","volume":"32","author":"El-Refaie","year":"2015","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2007.03.006","article-title":"Cationic transfersomes based topical genetic vaccine against hepatitis B","volume":"340","author":"Mahor","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0285","first-page":"2385","article-title":"Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation","volume":"8","author":"Freag","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0290","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2012.06.002","article-title":"Improvement of drug safety by the use of lipid-based nanocarriers","volume":"163","author":"Lim","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0300","series-title":"Liposomes: Methods and Protocols","first-page":"1","article-title":"Current trends in liposome research","volume":"vol. 1","author":"ElBayoumi","year":"2010"},{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0305","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pneurobio.2008.12.002","article-title":"Delivery of peptide and protein drugs over the blood\u2013brain barrier","volume":"87","author":"Brasnjevic","year":"2009","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0310","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/17425247.5.1.25","article-title":"Liposomal nanomedicines","volume":"5","author":"Fenske","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/469679","article-title":"Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)","volume":"2011","author":"Spuch","year":"2011","journal-title":"Journal of Drug Delivery"},{"issue":"2","key":"10.1016\/j.jconrel.2016.11.025_bb0320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00702-005-0312-6","article-title":"Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease","volume":"113","author":"Stefanova","year":"2006","journal-title":"J. Neural Transm."},{"issue":"37","key":"10.1016\/j.jconrel.2016.11.025_bb0325","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.2174\/13816128113199990613","article-title":"Targeted drug delivery across the blood brain barrier in Alzheimer's disease","volume":"19","author":"Rocha","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0330","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/138920012798356943","article-title":"Nanotechnologies: a strategy to overcome blood\u2013brain barrier","volume":"13","author":"De Rosa","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0335","first-page":"2191","article-title":"Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures","volume":"10","author":"Murugan","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0340","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1515\/ejnm-2014-0022","article-title":"Designing the future of nanomedicine: current barriers to targeted brain therapeutics","volume":"6","author":"Herda","year":"2014","journal-title":"Eur. J. Nanomed."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0345","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2011.07.030","article-title":"In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma","volume":"156","author":"Estella-Hermoso de Mendoza","year":"2011","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2016.11.025_bb0350","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.biomaterials.2010.10.027","article-title":"Curcumin-decorated nanoliposomes with very high affinity for amyloid-\u03b21\u201342 peptide","volume":"32","author":"Mourtas","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0355","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2014.04.050","article-title":"Multifunctional nanoliposomes with curcumin\u2013lipid derivative and brain targeting functionality with potential applications for Alzheimer disease","volume":"80","author":"Mourtas","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0360","article-title":"Functionalization with TAT-peptide enhances blood\u2013brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-\u00ce peptide","volume":"2013","author":"Sancini","year":"2013","journal-title":"J. Nanomed. Nanotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2016.11.025_bb0365","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s11095-013-1249-3","article-title":"Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies","volume":"31","author":"Markoutsa","year":"2014","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nano.2015.09.003","article-title":"The hunt for brain A\u03b2 oligomers by peripherally circulating multi-functional nanoparticles: potential therapeutic approach for Alzheimer disease","volume":"12","author":"Mancini","year":"2016","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"issue":"4\u20135","key":"10.1016\/j.jconrel.2016.11.025_bb0375","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1051\/lait:2007013","article-title":"The properties of liposomes produced from milk fat globule membrane material using different techniques","volume":"87","author":"Thompson","year":"2007","journal-title":"Lait"},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0380","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.drudis.2010.02.009","article-title":"Nanonization strategies for poorly water-soluble drugs","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0385","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2012.08.042","article-title":"Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs","volume":"453","author":"Lu","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"26","key":"10.1016\/j.jconrel.2016.11.025_bb0390","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.2174\/092986712803251584","article-title":"Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes","volume":"19","author":"Silva","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0395","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.colsurfb.2013.09.030","article-title":"Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment","volume":"113","author":"Sood","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0400","article-title":"Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery","volume":"1\u20139","author":"Nasr","year":"2015","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40005-016-0228-1","article-title":"Nanoemulsions loaded Carbopol\u00ae 934 based gel for intranasal delivery of neuroprotective Centella asiatica extract: in-vitro and ex-vivo permeation study","volume":"46","author":"Jaiswal","year":"2016","journal-title":"J. Pharm. Investig."},{"issue":"12","key":"10.1016\/j.jconrel.2016.11.025_bb0410","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4155\/tde.13.116","article-title":"A critical appraisal of microemulsions for drug delivery: part I","volume":"4","author":"Sapra","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0415","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.addr.2012.09.018","article-title":"Microemulsion-based media as novel drug delivery systems","volume":"64","author":"Lawrence","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0420","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/10717544.2013.878857","article-title":"Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization","volume":"22","author":"Shah","year":"2015","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2016.11.025_bb0425","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/03639045.2011.625031","article-title":"Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease","volume":"38","author":"Shi","year":"2012","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0430","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1521-3773(19990401)38:7<884::AID-ANIE884>3.0.CO;2-K","article-title":"Dendrimers: from design to application\u2014a progress report","volume":"38","author":"Fischer","year":"1999","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0435","series-title":"Dendritic Molecules: Concepts, Syntheses, Perspectives","author":"Moorefield","year":"2008"},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0440","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1295\/polymj.17.117","article-title":"A new class of polymers: starburst-dendritic","volume":"17","author":"Tomalia","year":"1985","journal-title":"Polym. J."},{"issue":"11","key":"10.1016\/j.jconrel.2016.11.025_bb0445","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1021\/bm2008636","article-title":"Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid\u2013dendrimer aggregates morphology and cell toxicity","volume":"12","author":"Klementieva","year":"2011","journal-title":"Biomacromolecules"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0450","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1021\/mp2005627","article-title":"Phosphorus dendrimers affect Alzheimer's (A\u03b21\u201328) peptide and MAP-Tau protein aggregation","volume":"9","author":"Wasiak","year":"2012","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0455","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/13543776.2014.915943","article-title":"Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations","volume":"24","author":"Xu","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0460","author":"NCT02322021"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/srep28200","article-title":"Anti-obesity effect of intranasal administration of galanin-like peptide (GALP) in obese mice","volume":"6","author":"Kageyama","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jconrel.2016.11.025_bb0470","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0192623311409594","article-title":"Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man","volume":"39","author":"Pereira","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0480","series-title":"Advanced Healthcare Materials","first-page":"87","article-title":"Nanoparticles for diagnosis and\/or treatment of Alzheimer's disease","author":"Antimisiaris","year":"2014"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0485","first-page":"155","article-title":"Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil","volume":"8","author":"Raja Azalea","year":"2012","journal-title":"Iranian Journal of Pharmaceutical Sciences"},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0490","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.addr.2011.12.006","article-title":"Polymeric nanoparticles for drug delivery to the central nervous system","volume":"64","author":"Patel","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0495","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","article-title":"Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art","volume":"87","author":"Gastaldi","year":"2014","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2016.11.025_bb0500","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Advanced drug delivery reviews"},{"issue":"4","key":"10.1016\/j.jconrel.2016.11.025_bb0505","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/156720105774370267","article-title":"Engineering of nanoemulsions for drug delivery","volume":"2","author":"Sarker","year":"2005","journal-title":"Current Drug Delivery"},{"issue":"10","key":"10.1016\/j.jconrel.2016.11.025_bb0510","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s11095-013-1156-7","article-title":"Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases","volume":"30","author":"Bozda\u011f","year":"2013","journal-title":"Pharm. Res."},{"issue":"36","key":"10.1016\/j.jconrel.2016.11.025_bb0515","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.2174\/0929867321666140815124246","article-title":"Diagnostic and therapeutic uses of nanomaterials in the brain","volume":"21","author":"Garbayo","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001191.pub3","article-title":"Rivastigmine for Alzheimer's disease","volume":"2","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0525","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0530","article-title":"Galantamine for Alzheimer's disease and mild cognitive impairment","volume":"1","author":"Loy","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0535","author":"European Medicines Agency"},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0540","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/gps.1752","article-title":"Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease","volume":"22","author":"Jones","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jconrel.2016.11.025_bb0545","first-page":"95","article-title":"Safety and efficacy of memantine extended-release in the management of Alzheimer's disease","volume":"5","author":"Corbett","year":"2013","journal-title":"Clin. Med. Insights Ther."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0550","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005592.pub2","article-title":"Huperzine A for Alzheimer's disease","volume":"2","author":"Li","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0555","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13346-013-0133-3","article-title":"Nanotechnology for CNS delivery of bio-therapeutic agents","volume":"3","author":"Amiji","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2016.11.025_bb0560","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4155\/tde.15.30","article-title":"Challenges and new strategies for therapeutic peptide delivery to the CNS","volume":"6","author":"McGowan","year":"2015","journal-title":"Ther. Deliv."},{"issue":"5","key":"10.1016\/j.jconrel.2016.11.025_bb0565","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jalz.2009.06.004","article-title":"Commentary on \u201cAlzheimer's disease drug development and the problem of the blood\u2013brain barrier\u201d","volume":"5","author":"S","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0570","author":"ClinicalTrials.org"},{"issue":"8","key":"10.1016\/j.jconrel.2016.11.025_bb0575","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2016.11.025_bb0580","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.3390\/ijms15033671","article-title":"Nanotoxicity overview: nano-threat to susceptible populations","volume":"15","author":"Li","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2016.11.025_bb0585","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s11095-013-1156-7","article-title":"Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases","volume":"30","author":"Pehlivan","year":"2013","journal-title":"Pharm. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916308367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916308367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T08:54:14Z","timestamp":1572425654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916308367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":116,"alternative-id":["S0168365916308367"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}